Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DMAC vs ABSI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DMAC Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–2 Matrix Metrics)
DMAC Overall Winner
6-Pillar Tally: DMAC 2 – 2 ABSI (2 Tie)
Matrix Metrics: DMAC 5 – 2 ABSI
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Absci Corporation (ABSI) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas ABSI carries 37.5/100 (SELL) at $7.72 (N/M Forward P/E, -9108.3% operating margin).
- Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile ABSI is in a Breakdown options structure phase (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DMAC vs ABSI
DMAC
Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
$8.41
-4.27% 1D
Market Cap
$503.1M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.74β · 98% Vol
Unified Composite Score
46.3
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
ABSI
Absci Corporation Common Stock
$7.72
-8.58% 1D
Market Cap
$1.6B
TTM Revenue
$1.5M
Forward P/E
N/M
Beta / 30D Vol
3.31β · 126% Vol
Unified Composite Score
37.5
SELL
Tech 27.0
Fund 51.0
Flow 71.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (DMAC 2 – 2 ABSI)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
ABSI
Revenue Growth (YoY)
+0.0%
-19.6%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$1.5M
Market Cap
$503.1M
$1.6B
3. Profitability & Quality
DMAC
Gross Margin
N/A
N/A
Operating Margin
0.0%
-9108.3%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-114.6%
-58.6%
4. Balance Sheet & Cash Flow
DMAC
Cash Generation (TTM)
-$32M
-$112M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$4.9M Net Cash
$10M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ABSI
Options Structure Phase
SURGE
BREAKDOWN
Current IV / %ile
106.3% (14th %ile)
169.1% (15th %ile)
Put/Call OI Skew
N/A
0.57x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DMAC (5) vs ABSI (2)| Institutional Metric | DMAC | ABSI | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $503.1M | $1.6B | ABSI | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | -19.6% | DMAC | |
| Operating Margin (TTM) | 0.0% | -9108.3% | DMAC | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -114.6% | -58.6% | ABSI | |
| 52-Week Range Position | 55% ($5–$11) | 53% ($2–$13) | DMAC | |
| Beta / 30D Volatility | 1.74β · 98% Vol | 3.31β · 126% Vol | DMAC | |
| Unified Institutional Score | 46.3 / 100 (HOLD) | 37.5 / 100 (SELL) | DMAC | |
| Trailing 12M Revenue (USD) | N/A | $1.5M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$32M ($4.9M Net Cash) | -$112M ($10M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DMAC +17.52 pp
3M Horizon
DMAC +40.02 pp
6M Horizon
ABSI +8.07 pp
1Y Horizon
ABSI +137.35 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | ABSI Revenue | DMAC Op. Margin | ABSI Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -1352.2% | N/A | DMAC |
| FY2020 | N/A | $0M | N/A | -278.3% | ABSI |
| FY2021 | N/A | $0M | N/A | -1573.4% | ABSI |
| FY2022 | N/A | $10M | N/A | -1857.5% | ABSI |
| FY2023 | N/A | $10M | N/A | -2020.2% | ABSI |
| FY2024 | N/A | $0M | N/A | -2401.6% | ABSI |
| FY2025 | N/A | $0M | N/A | -4297.0% | ABSI |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DMAC
SURGE
Current IV
106.3%
IV Percentile
14th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ABSI
BREAKDOWN
Current IV
169.1%
IV Percentile
15th %ile
Put/Call OI Skew
0.57x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ABSI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DMAC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ABSI Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DMAC vs ABSI Key Questions & Quantitative Answers
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Absci Corporation (ABSI) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). DMAC carries a Unified Composite Score of 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin), whereas ABSI carries 37.5/100 (SELL) at $7.72 (N/M Forward P/E, -9108.3% operating margin). Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile ABSI is in a Breakdown options structure phase (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABSI leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABSI at -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin). Across the 7-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while ABSI shifted +0.0%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABSI.
DMAC and ABSI trade at balanced relative valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus ABSI (-58.6% ROE) capital efficiency.
In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, ABSI carries 169.1% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.31β · 126% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ABSI vs DMAC · Reverse Pair
DMAC vs TRVI
· Sector Peer
DMAC vs VRCA
· Sector Peer
DMAC vs FENC
· Sector Peer
ABSI vs PRME
· Sector Peer
ABSI vs RLAY
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem